What was the primary driver of revenue growth in the second quarter of 2006?

The primary driver of revenue growth was the strong performance of the Companion Animal Group (CAG), which saw a 19.5% increase in revenue to $156.9 million. This growth was fueled by increased sales volume in instruments, consumables, rapid assay products, and laboratory and consulting services, as well as contributions from recent acquisitions.

How did the adoption of SFAS No. 123(R) impact the financial statements?

The adoption of SFAS No. 123(R) on January 1, 2006, required IDEXX to recognize share-based compensation expense at fair value. This resulted in an increase in reported expenses, particularly in operating expenses and cost of revenue, and a corresponding increase in net income impact from share-based compensation. It also affected the classification of certain tax benefits from stock option exercises, moving them from operating cash flows to financing cash flows.

What is the company's outlook on liquidity and capital resources?

IDEXX believes its current cash and cash equivalents, short-term investments, and cash generated from operations are sufficient to fund its operations, capital expenditures, and strategic growth needs. While cash and cash equivalents decreased in the first half of 2006 due to investing activities and share repurchases, the company maintains a healthy working capital position.

Are there any significant risks or uncertainties mentioned in the filing?

Yes, key risks include dependence on distributor purchasing patterns, competition and rapid technological change in its markets, reliance on single or limited sources for key materials, the complexity of manufacturing biologic products, protection of proprietary technologies, potential negative impacts from changes in diagnostic testing trends, risks associated with international operations, and the potential loss of key management personnel. The company also noted risks related to securities litigation and the volatility of its stock price.

IDXX 10-Q Quarterly Report Q2 FY2006 — Revenue, Net Income, EPS

Summary

IDEXX Laboratories, Inc. reported strong financial results for the second quarter and first half of 2006, demonstrating robust revenue growth across its key segments. Total revenue increased by 19% year-over-year for the quarter and 15% for the six-month period, driven primarily by strong performance in the Companion Animal Group (CAG), which saw a 19.5% revenue increase in Q2. The company also experienced significant growth in its Food Diagnostics Group (FDG), up 28.9% in Q2. Profitability also improved, with operating income rising 28.2% for the quarter. The adoption of SFAS No. 123(R) for share-based compensation has impacted reported expenses and cash flows, but management highlighted improvements in gross profit margins and effective tax rates due to strategic initiatives and tax incentives. Key financial highlights include substantial revenue growth in the CAG segment, driven by instruments, consumables, and services, alongside notable expansion in the FDG segment due to strong demand for production animal products. The company also noted strategic acquisitions and investments aimed at enhancing its product portfolio and market reach. Despite a decrease in cash and cash equivalents due to investment activities and share repurchases, IDEXX maintains a healthy liquidity position, believing its current resources are sufficient to fund operations and strategic growth initiatives. Investors should note the ongoing impact of share-based compensation accounting changes and the company's continued focus on product innovation and market expansion.

Key Highlights

1Total revenue for Q2 2006 increased by 19% to $191.4 million, and for the six months ended June 30, 2006, revenue grew by 15% to $359.5 million, compared to the prior year periods.
2The Companion Animal Group (CAG) was a strong performer, with revenue up 19.5% in Q2 to $156.9 million, driven by instruments, consumables, and services, and up 15.6% for the first half of the year.
3The Food Diagnostics Group (FDG) also showed significant growth, with Q2 revenue increasing 28.9% to $19.4 million, primarily due to strong sales of production animal products.
4Gross profit for the total company increased by 22.9% in Q2 to $99.0 million, with gross margin improving to 51.8% from 50.2% in the prior year period.
5Operating income for Q2 2006 rose by 28.2% to $37.0 million, leading to an operating margin of 19.3%, up from 18.0% in Q2 2005.
6The adoption of SFAS No. 123(R) beginning January 1, 2006, resulted in increased share-based compensation expense, impacting net income and cash flows from operations, though this is a non-cash expense.
7The company's effective tax rate decreased in both Q2 and the first half of 2006 compared to the prior year, attributed to tax incentives and the release of a valuation allowance on international deferred tax assets.

IDEXX LABORATORIES INC /DE Quarterly Report for Q2 Ended Jun 30, 2006

Summary

Key Highlights

Frequently Asked Questions